ArticleAnnals of hematology2025

CXCL9 and IL-18: potential biomarkers for efficacy evaluation in refractory hemophagocytic lymphohistiocytosis treated with RED (ruxolitinib, emapalumab and dexamethasone).

Xuan Lan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.